Agonist News and Research

RSS

Diabetes drugs may reduce risk of opioid overdose and alcohol intoxication

Researchers examine the association between prescriptions of diabetes drugs and the incidence of alcohol intoxication and opioid overdose.

22 Oct 2024

Methadone more effective than buprenorphine in reducing treatment discontinuation

People with opioid use disorder in British Columbia who received methadone had a 37–40 per cent lower rate of treatment discontinuation compared with those who received buprenorphine/naloxone.

21 Oct 2024

New guidelines focus on preventing first strokes through healthy living

Healthy lifestyle behaviors, such as good nutrition, smoking cessation and being physically active, along with routine health screenings and managing risk factors for cardiovascular disease and stroke with medication, can help prevent individuals from having a first stroke.

21 Oct 2024

Ozempic and similar drugs may lower risks for opioid and alcohol use disorders

A new study published in the scientific journal Addiction has found that people with opioid or alcohol use disorder (OUD, AUD) who take Ozempic or similar medications to treat diabetic/weight-related conditions appear to have a 40% lower rate of opioid overdose and a 50% lower rate of alcohol intoxication than people with OUD and AUD who do not take Ozempic or similar medications.

17 Oct 2024

Semaglutide enhances cognitive abilities and reduces Alzheimer’s pathology in mice and human brain models

Researchers find that Semaglutide improves cognitive function and reduces amyloid and tau pathology in Alzheimer's disease models, while restoring oxytocin levels in both mice and human brain organoids.

14 Oct 2024

Semaglutide improves heart health and reduces weight in obese patients, but with side effects

Semaglutide significantly reduces cardiovascular events and adverse effects in overweight and obese patients. The study highlights semaglutide's superiority over other GLP-1 agonists for cardiovascular health.

14 Oct 2024

Liver X receptor beta offers new hope in treating depression and anxiety

Liver X receptor beta (LXRβ) shows potential in reducing depression and anxiety by improving neurogenesis, reducing neuroinflammation, and enhancing cognitive and emotional function. More research on LXR agonists could reveal new treatments for mental health disorders.

8 Oct 2024

Rice University leads development of innovative bioelectronic implant for obesity and diabetes

Rice University is part of a multiuniversity research team that has secured an award of up to $34.9 million from the Advanced Research Projects Agency for Health (ARPA-H) to accelerate the development of a bioelectronic implant designed to improve adherence for obesity and type 2 diabetes (T2D) treatment while reducing development and manufacturing costs.

3 Oct 2024

Scientists uncover two Crohn’s disease subtypes using lab-grown intestines, offering hope for personalized therapies

Researchers used stem-cell derived organoids from Crohn's disease patients to identify two molecular subtypes, paving the way for personalized treatments targeting specific disease characteristics.

2 Oct 2024

Regulating iron overload: Liraglutide's potential benefits

Researchers assess the role of liraglutide in regulating iron metabolism in a mouse model of hereditary hemochromatosis.

30 Sep 2024

New pipeline of drug candidates offers hope for effective MASLD treatments

Non-alcoholic fatty liver disease (NAFLD), recently reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD), has become the most prevalent chronic liver disease globally.

25 Sep 2024

Liraglutide activates key brain circuits to trigger weight loss in obesity

Researchers uncover how liraglutide targets specific brain regions to suppress appetite and promote significant weight loss through GLP-1 receptor activation.

23 Sep 2024

Bariatric surgery outperforms GLP-1 medications in protecting kidney function

A Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery was associated with a significant decrease in the progression of chronic kidney disease compared to those who received GLP-1 diabetes medications. The paper was published in Annals of Surgery.

20 Sep 2024

Telehealth app found to improve retention rates in opioid use disorder treatment

Patients who initiated treatment for opioid use disorder through a telehealth mobile app stayed with treatment at a greater rate over six months than those who started treatment in a physical clinic, a new study led by Oregon Health & Science University found.

17 Sep 2024

Activation of PPARβ/δ-AMPK pathway shown to slow liver fibrosis development

A study led by Manuel Vázquez Carrera, group leader at the Diabetes and Associated Metabolic Diseases Networking Biomedical Research Centre (CIBERDEM) at the University of Barcelona, reveals advances in the understanding and treatment of liver fibrosis, a serious complication in the context of metabolic fatty liver disease, also known as MASLD (metabolic dysfunction-associated steatotic liver disease).

17 Sep 2024

Review highlights mitochondrial dysfunction in cholestatic liver injury

Bile acids are essential signaling molecules derived from cholesterol metabolism in the liver and are crucial for the digestion and absorption of fats.

16 Sep 2024

Cannabidiol shows promise in treating cognitive disorders

Research reviews the therapeutic potential of cannabidiol (CBD) in treating cognitive impairments, highlighting positive effects in some trials while emphasizing the need for more comprehensive studies.

12 Sep 2024

Real-world evidence highlights safety profile of tirzepatide in managing type 2 diabetes

As more people with type 2 diabetes (T2D) are taking medications to help manage blood sugar levels and weight loss, concerns about whether these drugs are safe have emerged.

12 Sep 2024

Women experience greater weight loss with tirzepatide compared to men

All doses of tirzepatide, a medication approved in the EU to treat type 2 diabetes and obesity, consistently reduced body weight in women and men, but women experienced greater weight loss, according to new post hoc research to be presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

11 Sep 2024

Obesity medication liraglutide safe and effective in children under 12, research finds

The obesity medication liraglutide is safe and effective in children aged 6 to <12 years, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), and published simultaneously in the New England Journal of Medicine (NEJM), has found.

10 Sep 2024